All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with cirrhosis and with previous oesophagogastric variceal bleeding
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality due to rebleeding · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes mortality due to rebleeding compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Acute hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes acute hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Chronic hepatic encephalopathy · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes chronic hepatic encephalopathy compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
Uterine volume (cm³) · women with uterine fibroids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fibroid volume (cm³) · women with uterine fibroids
1 finding from 1 review
Haemoglobin (g/dL) · women with uterine fibroids
1 finding from 1 review
Preoperative bleeding: (PBAC < 75) ulipristal acetate 5 mg · women with uterine fibroids
GnRHa treatment showed no clear difference in preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal… compared with other medical therapies before any surgery (moderate certainty).
1 finding from 1 review
Preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal acetate 10 mg · women with uterine fibroids
GnRHa treatment showed no clear difference in preoperative bleeding: Reduction in bleeding to PBAC < 75 ulipristal… compared with other medical therapies before any surgery (moderate certainty).
1 finding from 1 review
Adverse events (hot flushes) · women with uterine fibroids
GnRHa treatment may leads to higher adverse events (hot flushes) compared with other medical therapies before any surgery (low certainty).
1 finding from 1 review
Relapse, drop‐outs classed as relapse, grouped by length of · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in relapse, drop‐outs classed as relapse, grouped by length of compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.98 [0.91, 1.07]
11 studies · 2014 participants
Moderate
RR 0.99 [0.8, 1.23]
1 study · 161 participants
Low
RR 1.07 [0.86, 1.33]
1 study · 132 participants
Moderate
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review